Hyesun Kim1, Jeong H Yi, Hee J Kwon, Christopher S Lee, Sung C Lee. 1. *Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea; †Jeil Eye Clinic, Gyunggi-do, South Korea; and ‡Department of Ophthalmology, Bundang CHA General Hospital, CHA University, Gyunggi-do, South Korea.
Abstract
PURPOSE: To report the results of treatments and therapeutic complications of retinal hemangioblastomas (RH). METHODS: Retrospective consecutive case series. Data from 32 patients (37 eyes) with RH were reviewed for characteristics of RH and treatment outcomes. RESULTS: Among 32 patients, we identified 73 RHs in 37 eyes. At baseline, 24 of 37 eyes (65%) had 20/50 visual acuity or better, 8 eyes (22%) had intermediate vision (20/400-20/50), and 5 eyes (13%) had poor vision (≤20/400). Seven RHs (9.6%) were located in the juxtapapillary area, and 66 RHs (90.4%) were located in peripheral area. Small RHs (54.8%; <0.5 mm in size) were treated with laser photocoagulation, moderate-sized RHs (24.7%; 0.5-3.0 mm in size) were treated with transpupillary thermotherapy, and large RHs (20.5%; >3.0 mm in size) were treated with a combination of transpupillary thermotherapy and cryotherapy. After treatment, 90% of small RHs regressed, whereas only 67% of large RHs regressed (P = 0.044). Peripheral RHs showed better response to treatment than juxtapapillary RHs (P = 0.010). Treatment-related complications occurred in 5 eyes (14%), and 1-step combination therapy was applied more frequently in the complication group (P = 0.048). CONCLUSION: Small RHs in peripheral areas may require aggressive treatment because they respond well to treatment. In larger RHs, staged treatment could reduce treatment-related complications. Transpupillary thermotherapy could be an effective method in tumor regression for moderate-to-large-sized RHs showing tumor regression rate of 70%.
PURPOSE: To report the results of treatments and therapeutic complications of retinal hemangioblastomas (RH). METHODS: Retrospective consecutive case series. Data from 32 patients (37 eyes) with RH were reviewed for characteristics of RH and treatment outcomes. RESULTS: Among 32 patients, we identified 73 RHs in 37 eyes. At baseline, 24 of 37 eyes (65%) had 20/50 visual acuity or better, 8 eyes (22%) had intermediate vision (20/400-20/50), and 5 eyes (13%) had poor vision (≤20/400). Seven RHs (9.6%) were located in the juxtapapillary area, and 66 RHs (90.4%) were located in peripheral area. Small RHs (54.8%; <0.5 mm in size) were treated with laser photocoagulation, moderate-sized RHs (24.7%; 0.5-3.0 mm in size) were treated with transpupillary thermotherapy, and large RHs (20.5%; >3.0 mm in size) were treated with a combination of transpupillary thermotherapy and cryotherapy. After treatment, 90% of small RHs regressed, whereas only 67% of large RHs regressed (P = 0.044). Peripheral RHs showed better response to treatment than juxtapapillary RHs (P = 0.010). Treatment-related complications occurred in 5 eyes (14%), and 1-step combination therapy was applied more frequently in the complication group (P = 0.048). CONCLUSION: Small RHs in peripheral areas may require aggressive treatment because they respond well to treatment. In larger RHs, staged treatment could reduce treatment-related complications. Transpupillary thermotherapy could be an effective method in tumor regression for moderate-to-large-sized RHs showing tumor regression rate of 70%.
Authors: Carlos Andrés Valdés-Lara; Jose Arturo Oyervides-Alvarado; Juan Manuel Elizondo-Camacho; Dhariana Acón-Ramírez; Jose Gerardo García-Aguirre Journal: Case Rep Ophthalmol Date: 2020-01-10
Authors: Anass Hajjaj; Koen A van Overdam; Rogier A Oldenburg; Anna E Koopmans; Ans M W van den Ouweland; Annelies de Klein; Emine Kiliç Journal: Acta Ophthalmol Date: 2020-01-30 Impact factor: 3.761